Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry A Jacobson

Showing results (91-100 of 182) with videos related to

Pageof 19
Sort By:
Journal of Hospital Medicine|June 10, 2010
Health literacy and the quality of physician-patient communication during hospitalizationSunil Kripalani, Terry A Jacobson, Ileko C Mugalla, et al.
The American Journal of Clinical Nutrition|June 11, 2008
Conclusions and recommendations from the symposium, Beyond Cholesterol: Prevention and Treatment of Coronary Heart Disease with n-3 Fatty AcidsRichard J Deckelbaum, Alexander Leaf, Dariush Mozaffarian, et al.
Cardiovascular Drugs and Therapy|August 8, 2016
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed HyperlipidemiaRobert S Rosenson, Terry A Jacobson, David Preiss, et al.
The American Journal of Medicine|January 4, 2014
Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemiaJennifer B Christian, Bhakti Arondekar, Erin K Buysman, et al.
Atherosclerosis|June 24, 2014
Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targetsPeter P Toth, Michael Grabner, Rajeshwari S Punekar, et al.
The American Journal of Cardiology|August 16, 2011
Estimating health and economic benefits from using prescription omega-3 fatty acids in patients with severe hypertriglyceridemiaStuart Samuel, Barbara Peskin, Bhakti Arondekar, et al.
Journal of Clinical Lipidology|September 27, 2012
Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemiaJennifer B Christian, Bhakti Arondekar, Erin K Buysman, et al.
Cardiovascular Drugs and Therapy|June 1, 2016
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed HyperlipidemiaRobert S Rosenson, Terry A Jacobson, David Preiss, et al.
The American Journal of Cardiology|September 22, 2010
30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006Jerome D Cohen, Mark J Cziraky, Qian Cai, et al.
Journal of Clinical Lipidology|May 6, 2014
An assessment by the Statin Intolerance Panel: 2014 updateJohn R Guyton, Harold E Bays, Scott M Grundy, et al.
Pageof 19

Showing results (91-100 of 182) with videos related to

Sort By:
Pageof 19
Journal of Hospital Medicine|June 10, 2010
Health literacy and the quality of physician-patient communication during hospitalizationSunil Kripalani, Terry A Jacobson, Ileko C Mugalla, et al.
The American Journal of Clinical Nutrition|June 11, 2008
Conclusions and recommendations from the symposium, Beyond Cholesterol: Prevention and Treatment of Coronary Heart Disease with n-3 Fatty AcidsRichard J Deckelbaum, Alexander Leaf, Dariush Mozaffarian, et al.
Cardiovascular Drugs and Therapy|August 8, 2016
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed HyperlipidemiaRobert S Rosenson, Terry A Jacobson, David Preiss, et al.
The American Journal of Medicine|January 4, 2014
Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemiaJennifer B Christian, Bhakti Arondekar, Erin K Buysman, et al.
Atherosclerosis|June 24, 2014
Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targetsPeter P Toth, Michael Grabner, Rajeshwari S Punekar, et al.
The American Journal of Cardiology|August 16, 2011
Estimating health and economic benefits from using prescription omega-3 fatty acids in patients with severe hypertriglyceridemiaStuart Samuel, Barbara Peskin, Bhakti Arondekar, et al.
Journal of Clinical Lipidology|September 27, 2012
Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemiaJennifer B Christian, Bhakti Arondekar, Erin K Buysman, et al.
Cardiovascular Drugs and Therapy|June 1, 2016
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed HyperlipidemiaRobert S Rosenson, Terry A Jacobson, David Preiss, et al.
The American Journal of Cardiology|September 22, 2010
30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006Jerome D Cohen, Mark J Cziraky, Qian Cai, et al.
Journal of Clinical Lipidology|May 6, 2014
An assessment by the Statin Intolerance Panel: 2014 updateJohn R Guyton, Harold E Bays, Scott M Grundy, et al.
Pageof 19